Corrects company name in paragraph 1
May 21 (Reuters) - Moderna MRNA.O said on Wednesday it had withdrawn the pending application for its flu and COVID combination vaccine candidate for adults aged 50 years and older.
The company would resubmit the application later this year with vaccine efficacy data from the late-stage trial of its experimental seasonal influenza vaccine, it said.
(Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva)
((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.